{"id":"prednisolone-farnesylate","rwe":[{"pmid":"12220695","year":"2002","title":"Treatment of the chronic inflammation in peripheral target tissue improves the crushed nerve recovery in the rat: histopathological assessment of the nerve recovery.","finding":"","journal":"Journal of the neurological sciences","studyType":"Clinical Study"},{"pmid":"8008705","year":"1994","title":"Diffusion and metabolism of prednisolone farnesylate in viable skin of the hairless mouse.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"1293331","year":"1992","title":"[A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks].","finding":"","journal":"The Journal of toxicological sciences","studyType":"Clinical Study"},{"pmid":"1293330","year":"1992","title":"[A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks].","finding":"","journal":"The Journal of toxicological sciences","studyType":"Clinical Study"},{"pmid":"1293328","year":"1992","title":"[Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa].","finding":"","journal":"The Journal of toxicological sciences","studyType":"Clinical Study"}],"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"prednisolone 21-all-trans-farnesylate","offLabel":[],"synonyms":["prednisolone farnesylate","prednisolone 21-all-trans-farnesylate"],"timeline":[],"approvals":[],"brandName":"Prednisolone 21-All-Trans-Farnesylate","ecosystem":[],"mechanism":{"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"Imagine your body's immune system as a fire alarm that sounds when it detects an intruder. Prednisolone farnesylate is like a fire alarm silencer that reduces the alarm's sensitivity, allowing the fire department (your body's natural response) to respond more calmly and reducing the risk of damage.","oneSentence":"Prednisolone farnesylate works by attaching to specific receptors in the body to reduce inflammation and suppress the immune system.","technicalDetail":"Prednisolone farnesylate exerts its anti-inflammatory effects by binding to glucocorticoid receptors, which then translocate to the nucleus and regulate the expression of genes involved in inflammation, leading to a decrease in the production of pro-inflammatory cytokines and an increase in anti-inflammatory cytokines."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2248","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prednisolone farnesylate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:25:00.704266","biosimilars":[],"competitors":[],"genericName":"prednisolone farnesylate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"5347","NDDF":"002155","UNII":"359F2816ER","CHEBI":"CHEBI:32043","VANDF":"4017988","INN_ID":"535","RXNORM":"8638","UMLSCUI":"C0214080","KEGG_DRUG":"D01998","DRUGBANK_ID":"DB00860","PDB_CHEM_ID":" TUA","PUBCHEM_CID":"5282229","SNOMEDCT_US":"116601002","MESH_DESCRIPTOR_UI":"D011239","MESH_SUPPLEMENTAL_RECORD_UI":"C080069"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":13,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2002 Oct 15","pmid":"12220695","title":"Treatment of the chronic inflammation in peripheral target tissue improves the crushed nerve recovery in the rat: histopathological assessment of the nerve recovery.","journal":"Journal of the neurological sciences"},{"date":"1994 Mar","pmid":"8008705","title":"Diffusion and metabolism of prednisolone farnesylate in viable skin of the hairless mouse.","journal":"Pharmaceutical research"},{"date":"1992 Nov","pmid":"1293331","title":"[A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks].","journal":"The Journal of toxicological sciences"},{"date":"1992 Nov","pmid":"1293330","title":"[A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks].","journal":"The Journal of toxicological sciences"},{"date":"1992 Nov","pmid":"1293328","title":"[Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa].","journal":"The Journal of toxicological sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Prednisolone 21-All-Trans-Farnesylate is a small molecule that acts as a glucocorticoid receptor agonist. It belongs to the drug class of glucocorticoid receptor agonists.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}